Sun, Kunkun

PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

Zheng, B., Ren, T., Huang, Y., Sun, K., Wang, S., Bao, X., Liu, K., & Guo, W. (2018) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment

Cited by 151

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Xie, L., Xu, J., Sun, X., Guo, W., Gu, J., Liu, K., Zheng, B., Ren, T., Huang, Y., Tang, X., et al. (2020) · Journal for ImmunoTherapy of Cancer

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 145

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres

Xie, L., Xu, J., Sun, X., Li, X., Liu, K., Liang, X., Zhou, Z., Zhuang, H., Sun, K., Wu, Y., et al. (2021) · Oncology Letters

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 19

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

Xie, L., Liang, X., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Tang, X., Li, X., Zhan, X., et al. (2023) · BMC Cancer

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 14

Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study

Xie, L., Xu, J., Sun, X., Liu, K., Sun, K., Li, Y., Liu, R., Wang, D., Shao, S., Chen, Z., et al. (2025) · Nature Communications

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 3